Susquehanna International Group, LLP Tcr2 Therapeutics Inc. Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $186,002 - $365,029	-77,501 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $225,129 - $409,952	49,155 Added 173.41%	77,501 $361,000
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $39,862 - $86,667	-4,723 Reduced 14.28%	28,346 $241,000
Q2 2021 Aug 11, 2021	BUY	$16.41 - $24.71 $111,374 - $167,706	6,787 Added 25.82%	33,069 $543,000
Q1 2021 May 17, 2021	SELL	$20.38 - $34.07 $306,719 - $512,753	-15,050 Reduced 36.41%	26,282 $580,000
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $557,327 - $957,135	29,333 Added 244.46%	41,332 $1.28 Million
Q3 2020 Nov 16, 2020	SELL	$13.1 - $20.69 $366,053 - $578,140	-27,943 Reduced 69.96%	11,999 $244,000
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $124,894 - $323,267	19,185 Added 92.43%	39,942 $614,000
Q1 2020 May 15, 2020	BUY	$6.01 - $16.01 $124,749 - $332,319	20,757 New	20,757 $161,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.